Investors have been cheering about Moderna‘s (NASDAQ: MRNA) ability to bring a coronavirus vaccine to market in less than a year — and post more than a billion dollars in profit in the first full quarter of sales. The stock climbed 434% last year. And in the first half of 2021 it advanced 125%.